Table 3.
Comparison of Our Baseline BALF and Plasma Biomarker Concentrations with Prior Studies
| Biomarker* | Site | Baseline concentrations from prior studies§ | Mean Baseline Concentration in Our Study mean±SD, n=89 | Median Baseline Concentration in Our Study Median (IQR), n=89 | |
|---|---|---|---|---|---|
| Author | Concentration | ||||
| GCSF | Plasma | Suratt (2009) | Survivors: 188(80–540) Non-survivors: 207 (74–887) |
2213.6±14658.4 | 46.5 (20.9–122.7) |
| IL-1β | BALF | Park (2001) | 9.8 (4.4–18.9) | 238.5±1370.4 | 13.8 (2.6–104.9) |
| Goodman (1996) | Mean ~ 10,000 | ||||
| Ranieri (1999) | Mean ~900 | ||||
| IL-1ra | BALF | Park (2001) | 1829.2 (1124.3–6868.3) | 3905.6±7336.4 | 1729.9 (593.6–3214.0) |
| Donnelly (1996) | 820 (0–18,900) | ||||
| Ranieri (1999) | 16,503±14,935 | ||||
| Plasma | Parsons (1997) | ~15,000 (1,000–38,000) | 6727.0±17427.5 | 2380.4 (1313.4–4754.6) | |
| Ranieri (1999) | 4,218±3,645 | ||||
| IL-6 | BALF | Park (2001) | 1229.5 (263.3–3232.6) | 796.0±2320.5 | 145.3 (33.5–455.9) |
| Gadek (1999) | 282±145 | ||||
| Ranieri (1999) | Mean ~9,000 | ||||
| Plasma | Calfee (2007) | Trauma: 300 (128–674) Non-trauma: 259 (100–850) |
403.5±1829.8 | 81.7 (40.9–172.0) | |
| Ranieri (1999) | Mean −200 | ||||
| IL-8 | BALF | Goodman (1996) | Mean ~ 400 | 2407.6±8870.3 | 486.4 (253.5–1390.6) |
| Gadek (1999) | 2849±1458 | ||||
| Ranieri (1999) | Mean ~10,000 | ||||
| Plasma | Calfee (2007) | Trauma: 21 (20–59) Non-trauma: 44 (20–103) |
86.1±419.2 | 19.9 (19.8–35.2) | |
| Ranieri (1999) | Mean ~100 | ||||
| IL-10 | BALF | Park (2001) | 4.8 (1.5–9.3) | 7.4±13.4 | 3.6 (3.6–3.6)ll |
| Donnelly (1996) | 100 (0–1600) | ||||
| Plasma | Parsons (1997) | ~125,000 (50,000–300,000) | 39.6±159.2 | 14.3 (14.3–14.3)†† | |
| LTB4 | BALF | Gadek (1999) | 596±495.2 | 126.9±496.2 | 20.5 (9.3–31.3) |
| MCP-1 | BALF | Goodman (1996) | Mean ~ 1000 | 1122.9±2094.4 | 534.7 (185.2–1318.5) |
| PMNs† | BALF | Ranieri (1999) | Mean ~ 75 | 52.8±31.5 | 54.0 (25.5–82.8) |
| RAGE | Plasma | Calfee (2008) | Survivors: ~3900 (2000–8000) Non-survivors: ~5500 (2500–10,000) |
386.8±630.9 | 261.5 (137.6–438.4) |
| sFasL | BALF | Matute-Bello (1999) | Mean ~ 150 | 39.3±2.0 | 39.0 (39.0–39.0)ll |
| SP-D | Plasma | Calfee (2007) | Trauma: 58,000 (45,000–78,000) Non-trauma: 95,000 (45,000–211,000) |
186.9±253.9 | 122.4 (56.0–205.6) |
| TNF-α | BALF | Ranieri (1999) | Mean~750 | 17.3±55.1 | 3.8 (3.8–7.9)** |
| Plasma | Ranieri (1999) | Mean ~1,000 | 15.4±2.0 | 15.4 (15.4–15.4)†† | |
| vWF‡ | Plasma | Ware (2001) | ~250 (150–450) | 453.0±1058.2 | 248.4 (155.5–544.2) |
| Calfee (2007) | Trauma: 226 (142–331) Non-trauma: 355 (215–551) |
||||
Data are presented as pg/mL, except PMN
data are presented as % of total cells, and vWF
data are presented as % control.
Data presented as mean±SD or median (IQR), as available in prior literature. Use of ‘~’ notes that values are approximated from graphs and charts within that particular prior study. Many prior studies noted means in graphs but did not specifically define SD; this is noted by use of ‘mean~’.
BALF concentrations of IL-10 and sFasL in 75% of participants in our study were at or below the detection limit or our assay.
BALF concentrations of TNF-α in at least 50% of participants in our study were at or below the detection limit or our assay.
Plasma concentrations of IL-10 and TNF-α in 75% of participants in our study were at or below the detection limit or our assay.